Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28468645
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 BMC+Psychiatry
2017 ; 17
(1
): 161
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
What is the significance of onconeural antibodies for psychiatric symptomatology?
A systematic review
#MMPMID28468645
Sæther SG
; Schou M
; Kondziella D
BMC Psychiatry
2017[May]; 17
(1
): 161
PMID28468645
show ga
BACKGROUND: Patients with intracellular onconeural antibodies may present with
neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association
between well-characterized onconeural antibodies and psychiatric symptoms in
patients with and without paraneoplastic central nervous system syndromes.
METHODS: Eligible studies were selected from 1980 until February 2017 according
to standardized review criteria and evaluated using Quality Assessment of
Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the
psychiatric symptomatology of onconeural antibody positive patients and the
prevalence of onconeural antibodies in patients with psychiatric disorders.
RESULTS: Twenty-seven studies met the inclusion criteria. Six studies reported on
the prevalence of well-characterized onconeural antibodies in patients with
different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in
controls was available from three studies, ranging from 0% to 2.8%. Data
heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found
well-characterized onconeural antibodies in 3.5% and 0% of patients with
psychotic and depressive syndromes, respectively. CONCLUSIONS: The available
evidence suggests that the prevalence of well-characterized onconeural antibodies
in patients with psychiatric disorders is generally low. However, the question
whether onconeural antibodies are important in select patients with a purely
psychiatric phenotype needs to be addressed by appropriately designed studies in
the future.